EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 217 / Numéro 3-4 (2023) Biologie Aujourd’hui, 217 3-4 (2023) 161-182 References
Free Access
Issue
Biologie Aujourd’hui
Volume 217, Number 3-4, 2023
Page(s) 161 - 182
DOI https://doi.org/10.1051/jbio/2023028
Published online 29 novembre 2023
  • Abdallah, C.G., Sanacora, G., Duman, R.S., Krystal, J.H. (2018). The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacol Ther, 190, 148-158. [CrossRef] [PubMed] [Google Scholar]
  • Alaux-Cantin, S., Buttolo, R., Houchi, H., Jeanblanc, J., Naassila, M. (2015). Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. Addict Biol, 20, 890-901. [CrossRef] [PubMed] [Google Scholar]
  • Aleksandrova, L.R., Phillips, A.G. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci, 42, 929-942. [CrossRef] [PubMed] [Google Scholar]
  • Ardinger, C.E., Winkler, G., Lapish, C.C., Grahame, N.J. (2021). Effect of ketamine on binge drinking patterns in Crossed High Alcohol-Preferring (CHAP) mice. Alcohol, 97, 31-39. [CrossRef] [PubMed] [Google Scholar]
  • Autry, A.E., Monteggia, L.M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev, 64, 238-258. [CrossRef] [PubMed] [Google Scholar]
  • Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.-F., Ege T., Kavalali, E.T., Monteggia, L.M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 475, 91-95. [CrossRef] [PubMed] [Google Scholar]
  • Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, S., Krystal. J.H. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47, 351-354. [CrossRef] [PubMed] [Google Scholar]
  • Bird, C.I., Nadav V., Modlin L., Rucker, J.J.H. (2021). Psilocybin and MDMA for the treatment of trauma-related psychopathology. Int Rev Psychiatry (Abingdon, England), 33, 229-249. [Google Scholar]
  • Bonhomme, V., Vanhaudenhuyse, A., Demertzi, A., Bruno M.A., Jaque, O., Bahri, M.A., Plenevaux, A., Boly, M., Boveroux, P., Soddu, A., Brichant, J.F., Maquet, P., Laureys, S. (2016). Resting-state network-specific breakdown of functional connectivity during ketamine alteration of consciousness in volunteers. Anesthesiology 125, 873-888. [CrossRef] [PubMed] [Google Scholar]
  • Browne, C.A., Lucki, I. (2013). Antidepressant effects of ketamine: Mechanisms underlying fast-acting novel antidepressants. Front Pharmacol, 4, 161. [CrossRef] [PubMed] [Google Scholar]
  • Cameron, L.P., Tombari, R.J., Ju, L., Pell, A.J., Hurley, Z.Q., Ehinger, Y., Vargas, M.V., McCarroll, M.N., Taylor, J.C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L.J., Anderson, I.E., Zhang, G., Viswanathan, J., Brown, B.M., Tjia, M., Dunlap, L.E., Rabow, Z.T., Fiehn, O., Wulff, H., McCorvy, J.D., Lein, P.J., Kokel, D., Ron, D., Peters, J., Zuo, Y., Olson, D.E. (2021). A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 589, 474-479. [CrossRef] [PubMed] [Google Scholar]
  • Cannarozzo, C., Rubiolo, A., Casarotto, P., Castrén, E. (2023). Ketamine and its metabolite 2R,6R-hydroxynorketamine promote ocular dominance plasticity and release tropomyosin-related kinase B from inhibitory control without reducing perineuronal nets enwrapping parvalbumin interneurons. Eur J Neurosci, 57, 940-950. [CrossRef] [PubMed] [Google Scholar]
  • Cao, D., Yu, J, Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., Li, J, Cheng, J., Wang, S. (2022). Structure-based discovery of nonhallucinogenic psychedelic analogs. Science, 375, 403-411. [CrossRef] [PubMed] [Google Scholar]
  • Carhart-Harris, R.L. (2018). The entropic brain – Revisited. Neuropharmacology, 142, 167-178. [CrossRef] [PubMed] [Google Scholar]
  • Carhart-Harris, R.L., Friston K.J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. E.L. Barker (Ed). Pharmacol Rev, 71, 316-344. [CrossRef] [PubMed] [Google Scholar]
  • Carhart-Harris, R.L., Erritzoe, D., Williams, T., Stone, J.M., Reed, L.J., Colasanti, A., Tyacke, R.J., Leech, R., Malizia, A.L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R.G., Nutt, D.J. (2012). Neural correlates of the psychedelic state as determined by FMRI studies with psilocybin. Proc Natl Acad Sci USA, 109, 2138-2143. [CrossRef] [PubMed] [Google Scholar]
  • Carhart-Harris R.L., Leech R., Hellyer P.J., Shanahan M., Feilding A., Tagliazucchi E., Chialvo D.R., Nutt D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Human Neurosci, 8, 20. [Google Scholar]
  • Carhart-Harris, R.L., Muthukumaraswamy S., Roseman L., Kaelen M., Droog W., Murphy K., Tagliazucchi E., Schenberg, E.E., Nest, T., Orban, C., Leech, R., Williams, L.T., Williams, T.M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M.I., Nichols, D., Hellyer, P.J., Hobden, P., Evans, J., Singh, K.D., Wise, R.G., Curran, H.V., Feilding, A., Nutt, D.J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimagin. Proc Natl Acd Sci USA, 113, 4853-4858. [CrossRef] [PubMed] [Google Scholar]
  • Casarotto P.C., Girych, M., Fred, S.M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M.P., Kaurinkoski, K., Brunello, C.A., Steinzeig, A., Winkel, F., Patil, S., Vestring, S., Serchov, T., Diniz, C.R.A.F., Laukkanen, L., Cardon, I., Antila, H., Rog, T., Piepponen, T.P., Bramham, C.R., Normann, C., Lauri, S.E., Saarma, M., Vattulainen, I., Castrén, E. (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell, 184, 1299-1313. [CrossRef] [PubMed] [Google Scholar]
  • Castrén, E, Monteggia, L.M. (2021). Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry, 90, 128-136. [CrossRef] [PubMed] [Google Scholar]
  • Chen, W.Y., Huang M.C., Lin S.K. (2014). Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy, 9, 39. [CrossRef] [PubMed] [Google Scholar]
  • Condi, M., Sallerin, T., Devaux, C. (1972). Use of ketamine in the treatment of delirium tremens and medical delirium. Anesthesie, Analgesie, Reanimation, 29, 377-394. [PubMed] [Google Scholar]
  • Corne, R., Mongeau, R. (2019). Neurotrophic mechanisms of psychedelic therapy. Biologie Aujourd’hui, 213, 121-129. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  • Costa A.C., Joaquim H.P.G., Pedrazzi J.F.C., Pain A.O., Duque G., Aprahamian I. (2022). Cannabinoids in late life Parkinson’s disease and dementia: Biological pathways and clinical challenges. Brain Sci, 12, 1596. [CrossRef] [PubMed] [Google Scholar]
  • Crowley, N.A., Magee, S.N., Feng, M., Jefferson, S.J., Morris, C.J., Dao, N.C., Brockway, D.F., Luscher, B. (2019). Ketamine normalizes binge drinking-induced defects in glutamatergic synaptic transmission and ethanol drinking behavior in female but not male mice. Neuropharmacology, 149, 35-44. [CrossRef] [PubMed] [Google Scholar]
  • Dakwar, E., Anerella, C., Hart C.L, Levin F.R., Mathew S.J., Nunes, E.V. (2014). Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend, 136, 153-157. [CrossRef] [PubMed] [Google Scholar]
  • Dakwar, E., Levin, F., Hart, C.L., Basaraba, C., Choi, J., Pavlicova, M., Nunes, E.V. (2020). A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry, 177, 125-133. [CrossRef] [PubMed] [Google Scholar]
  • Das, R.K., Gale, G., Walsh, K., Hennessy, V.E., Iskandar, G., Mordecai, L.A., Brandner, B., Kindt, M., Curran, H.V., Kamboj, S.K. (2019). Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun, 10, 5187. [CrossRef] [PubMed] [Google Scholar]
  • De Gregorio, D., Aguilar-Valles, A., Preller, K.H., Heifets, B.D., Hibicke, M., Mitchell, J., Gobbi, G. (2021). Hallucinogens in mental health: Preclinical and clinical studies on LSD, Psilocybin, MDMA, and Ketamine. J Neurosci, 41, 891-900. [Google Scholar]
  • DiazGranados, N., Ibrahim, L.A., Brutsche, N.E., Ameli, R., Henter, I.D., Luckenbaugh, D.A., Machado-Vieira, R., Zarate, C.A. Jr. (2010). Rapid resolution of suicidal ideation after a single infusion of an N-Methyl-D-Aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry, 71, 1605-1611. [CrossRef] [PubMed] [Google Scholar]
  • Dworkin, R.H., Anderson, B.T., Andrews, N., Edwards, R.R., Grob, C.S., Ross, S., Satterthwaite, T.D., Strain, E.C. (2022). If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics. J Pain, 23, 1666-1679. [CrossRef] [PubMed] [Google Scholar]
  • Ebert, B., Mikkelsen, S., Thorkildsen C., Borgbjerg, F.M. (1999). Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol, 333, 99-104. [Google Scholar]
  • Ezquerra-Romano, I., Lawn, W., Krupitsky E., Morgan C.J.A. (2018). Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology, 142, 72-82. [CrossRef] [PubMed] [Google Scholar]
  • Feduccia, A.A., Mithoefer, M.C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuro-Psychopharmacol Biol Psychiatry, 84, 221-228. [CrossRef] [Google Scholar]
  • Franco, D., Zamudio, J., Blevins, K.M., Núñez-Larios, E.A., Ricoy, U.M., Iñiguez, S.D., Zavala, A.R. (2020). Early-life ketamine exposure attenuates the preference for ethanol in adolescent Sprague Dawley rats. Behav Brain Res, 389, 112626. [CrossRef] [PubMed] [Google Scholar]
  • Frohlich, J., Van Horn J.D. (2014). Reviewing the ketamine model for schizophrenia. J Psychopharmacol, 28, 287-302. [CrossRef] [PubMed] [Google Scholar]
  • Garel, N., McAnulty, C., Greenway, K.T., Lesperance, P., Miron, J.P., Rej, S., Richard-Devantoy, S., Jutras-Aswad, D. (2022). Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions. Drug Alcohol Depend, 239, 109606. [CrossRef] [PubMed] [Google Scholar]
  • Getachew, B., Tizabi, Y. (2019). Both ketamine and NBQX attenuate alcohol-withdrawal induced depression in male rats. J Drug Alcohol Res, 8, 236069. [PubMed] [Google Scholar]
  • Goldfine C.E., Tom J.J., Im D.D., Yudkoff B., Anand A., Taylor J.J., Chai P.R., Suzuki J. (2023). The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Front Psychiatry, 14, 11. [CrossRef] [Google Scholar]
  • Grabski, M., Borissova, A., Marsh, B., Morgan C.J.A., Curran, H.V. (2020). Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A Systematic Review. Behav Brain Res, 392, 112629. [CrossRef] [PubMed] [Google Scholar]
  • Grabsk, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., Hardy, L., Warren, F., Bloomfield, M., Borissova, A., Maschauer, E., Broomby, R., Price, R., Coathup, R., Gilhooly, D., Palmer, E., Gordon-Williams, R., Hill, R., Harris, J., Mollaahmetoglu, O.M., Curran, H.V., Brandner, B., Lingford-Hughes, A., Morgan, C.J.A. (2022). Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry 179, 152-162. [CrossRef] [PubMed] [Google Scholar]
  • Grant, B.F., Harford, T.C. (1995). Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey. Drug Alcohol Depend, 39, 197-206. [CrossRef] [MathSciNet] [Google Scholar]
  • Hameed, M., Prasad, S., Jain, E., Dogrul, B.N., Al-Oleima, T.A., Pokhrel, B., Chowdhury, S., Co, E.L., Mitra, S., Quinonez, J., Ruxmohan, S., Stein, J. (2023). Medical cannabis for chronic nonmalignant pain management. Curr Pain Headache Rep, 27, 57-63. [CrossRef] [PubMed] [Google Scholar]
  • Hasbi, A., Madras B.K., George S.R. (2023). Endocannabinoid system and exogenous cannabinoids in depression and anxiety: A review. Brain Sci, 13, 325. [CrossRef] [PubMed] [Google Scholar]
  • Hasin, D.S., Stinson F.S., Ogburn E., Grant B.F. (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results From the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry, 64, 830-842. [CrossRef] [PubMed] [Google Scholar]
  • Heifets, B.D., Bentzley B.S, Williams N., Schatzberg A.F. (2021). Unraveling the opioid actions of S-Ketamine and R-Ketamine: Comment on Bonaventura et al. Mol Psychiatry, 26, 6104-6106. [CrossRef] [PubMed] [Google Scholar]
  • Hess, E.M., Riggs, L.M., Michaelides, M., Gould T.D. (2022). Mechanisms of ketamine and its metabolites as antidepressants. Biochem Pharmacol, 197, 114892. [CrossRef] [PubMed] [Google Scholar]
  • Highland J.N., Farmer, C.A., Zanos, P., Lovett, J., Zarate, C.A. Jr., Moaddel, R., Gould, T.D. (2022). Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans. J Psychopharmacol, 36, 170-182. [CrossRef] [PubMed] [Google Scholar]
  • Holleran K.M., Wilson H.H., Fetterly T.L., Bluett R.J., Centanni S.W., Gilfarb R.A., Rocco L.E., Patel S., Winder D.G. (2016). Ketamine and MAG lipase inhibitor-dependent reversal of evolving depressive-like behavior during forced abstinence from alcohol drinking. Neuropsychopharmacology, 41, 2062-2071. [CrossRef] [PubMed] [Google Scholar]
  • Holzhauer, C.G., Cucciare, M., Epstein E.E. (2020). Sex and gender effects in recovery from alcohol use disorder. Alcohol Res, 40, 03. [CrossRef] [PubMed] [Google Scholar]
  • Jeanblanc, J., He, D.Y., Mc, Gough, N.N., Logrip, M.L., Phamluong, K., Janak, P.H., Ron, D. (2006). The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci, 26, 1457-1464. [CrossRef] [PubMed] [Google Scholar]
  • Jeanblanc, J., He, D.Y., Carnicella, S., Kharazia, V., Janak, P.H., Ron, D. (2009). Endogenous BDNF in the dorsolateral striatum gates alcohol drinking. J Neurosci, 29, 13494-13502. [CrossRef] [PubMed] [Google Scholar]
  • Jeanblanc, J., Coune, F. Botia, B., Naassila, M. (2014). Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by memantine. Addiction Biology, 19, 758-769. [CrossRef] [PubMed] [Google Scholar]
  • Jelen, L.A., Young, A.H., Stone J.M. (2021). Ketamine: A tale of two enantiomers. J Psychopharmacol, 35, 109-123. [CrossRef] [PubMed] [Google Scholar]
  • Joffe, M.E., Centanni, S.W., Jaramillo, A.A., Winder, D.G., Conn P.J. (2018). Metabotropic glutamate receptors in alcohol use disorder: Physiology, plasticity, and promising pharmacotherapies. ACS Chem Neurosci, 9, 2188-2204. [CrossRef] [PubMed] [Google Scholar]
  • Kadriu, B., Greenwald, M., Henter, I.D., Gilbert, J.R., Kraus, C., Park, L.T., Zarate, C.A. (2020). Ketamine and serotonergic psychedelics: Common mechanisms underlying the effects of rapid-acting antidepressants. Int J Neuropsychopharmacol, 24, 8-21. [Google Scholar]
  • Kavalali, E.T., Monteggia, L.M. (2012). Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry, 169, 1150-1156. [CrossRef] [PubMed] [Google Scholar]
  • Klein, K., Zanger, U.M. (2013). Pharmacogenomics of cytochrome P450 3A4: Recent progress toward the “missing heritability” problem. Front Genetics, 4, 12. [CrossRef] [Google Scholar]
  • Kohtala, S. (2021). Ketamine-50 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep, 73, 323-345. [CrossRef] [PubMed] [Google Scholar]
  • Kohtala, S., Theilmann, W., Rosenholm, M., Müller, H.K., Kiuru, P., Wegener, G., Yli-Kauhaluoma, J., Rantamäki, T. (2019). Ketamine-induced regulation of TrkB-GSK3β signaling is accompanied by slow EEG oscillations and sedation but is independent of hydroxynorketamine metabolites. Neuropharmacology, 157, 107684. [CrossRef] [PubMed] [Google Scholar]
  • Kokkinou, M., Ashok, A.H., Howes, O.D. (2018). The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry, 23, 59-69. [CrossRef] [PubMed] [Google Scholar]
  • Kolp, E., Young, S.A.M., Freidman, H., Krupitsky, E., Jansen, K., O’Connor, L-A. (2007). Ketamine-enhanced psychotherapy: Preliminary clinical observations on its effects in treating death anxiety. Int J Transpersonal Studies, 26, 1-17. [CrossRef] [Google Scholar]
  • Krupitsky, E.M., Grinenko, A.Y. (1997). Ketamine Psychedelic Therapy (KPT): A review of the results of ten years of research. J Psychoact Drugs, 29, 165-183. [CrossRef] [PubMed] [Google Scholar]
  • Krupitsky, E.M., Grinenko, A.Y., Berkaliev, T.N., Paley, A.I., Tetrov, U.N, Mushkov, K.A., Borodikin, Y.S. (1992). The combination of psychedelic and aversive approaches in alcoholism treatment: The affective contra-attribution method. Alcohol Treat Q, 9, 99-105. [CrossRef] [Google Scholar]
  • Kvam, T.-M., Stewart, L.H., Andreassen, O.A. (2018). Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskr Nor Legeforen, 138(18). doi.org/10.4045 [Google Scholar]
  • Li, J., Areal, C.C., Toffa, D.H., Citherlet, D., Deacon, C., Jutras-Aswad, D., Keezer, M.R., Nguyen, D.K. (2023). Use of non-medical cannabis in epilepsy: A scoping review. Front Neurol, 14, 1132106. [CrossRef] [PubMed] [Google Scholar]
  • Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S. (2021). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329, 959-964. [Google Scholar]
  • Lin, P.Y., Ma, Z.Z., Mahgoub, M., Kavalali, E.T., Monteggia, L.M. (2021). A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action. Cell Rep, 36, 109513. [CrossRef] [PubMed] [Google Scholar]
  • Lydic, R., Baghdoyan, H.A. (2002). Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep. Sleep, 25, 617-622. [PubMed] [Google Scholar]
  • McAndrew, A., Lawn, W., Stevens, T., Porffy, L., Brandner, B., Morgan, C.J. (2017) A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. Trials, 18, 159. [CrossRef] [PubMed] [Google Scholar]
  • McEwen, B.S. (1999). Permanence of brain sex differences and structural plasticity of the adult brain. Proc Nal Acad Sci USA, 96, 7128-7130. [CrossRef] [PubMed] [Google Scholar]
  • McGinnis, M.M., Parrish, B.C., McCool, B.A. (2020). Withdrawal from chronic ethanol exposure increases postsynaptic glutamate function of insular cortex projections to the rat basolateral amygdala. Neuropharmacology, 172, 108129. [CrossRef] [PubMed] [Google Scholar]
  • Meinhardt, M.W., Hansson, A.C., Perreau-Lenz, S., Bauder-Wenz, C., Stählin, O., Heilig, M., Harper, C., Drescher, K.U., Spanagel, R., Sommer, W.H. (2013). Rescue of infralimbic MGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J Neurosci, 33, 2794-2806. [CrossRef] [PubMed] [Google Scholar]
  • Meinhardt, M.W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., Hansson, A.C., Köhr, G., Meier, N., von Bohlen und Halbach, O., Bell, R.L., Endepols, H., Neumaier, B., Schönig, K., Bartsch, D., Naassila, M., Spanagel, R., Sommer, W.H. (2021). Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv, 7, eabh2399. [CrossRef] [PubMed] [Google Scholar]
  • Mendes, F.R., dos Santos Costa, C., Wiltenburg, V.D., Morales-Lima, G., Fernandes, J.A.B., Filev, R. (2022). Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neurosci, 3, 100025. [CrossRef] [Google Scholar]
  • Mertens, L.J., Preller K.H. (2021). Classical psychedelics as therapeutics in psychiatry – Current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry, 54, 176-190. [CrossRef] [PubMed] [Google Scholar]
  • Modaresi, F., Talachian, K. (2022). The characteristics of clinical trials on cannabis and cannabinoids: A review of trials for therapeutic or drug development purposes. Pharmaceutical Med, 36, 387-400. [CrossRef] [PubMed] [Google Scholar]
  • Mollaahmetoglu, O.M., Keeler, J., Ashbullby, K.J., Ketzitzidou-Argyri, E., Grabski M., Morgan C.J.A. (2021). “This is something that changed my life”: A qualitative study of patients experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry, 12, 695335. [CrossRef] [PubMed] [Google Scholar]
  • Moreno, J.L., Holloway, T., Albizu, L., Sealfon, S.C., González-Maeso, J. (2011). Metabotropic glutamate MGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett, 493, 76-79. [CrossRef] [PubMed] [Google Scholar]
  • Morgan, C.J.A., Curran, H.V., Independent Scientific Committee on Drugs. (2012). Ketamine use: A review. Addiction, 107, 27-38. [CrossRef] [PubMed] [Google Scholar]
  • Morisot, N., Ron, D. (2017). Alcohol-dependent molecular adaptations of the NMDA receptor system. Genes, Brain, Behav, 16, 139-148. [CrossRef] [PubMed] [Google Scholar]
  • Olson, D.E. (2021). The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 4, 563-567. [CrossRef] [PubMed] [Google Scholar]
  • Orhurhu, V., Orhurhu, M.S., Bhatia, A., Cohen S.P. (2019). Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesth Analg, 129, 241-254. [CrossRef] [PubMed] [Google Scholar]
  • Orsolini, L., Chiappini, S., Volpe, U., De Berardis, D., Latini, R., Papanti, G.D., Corkery, A.J.M. (2019). Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): A systematic review. Medicina (Kaunas, Lithuania), 55, 525. [CrossRef] [PubMed] [Google Scholar]
  • Pandey, S.C. (2016). A critical role of brain-derived neurotrophic factor in alcohol consumption. Biol Psychiatry, 79, 427-429. [CrossRef] [PubMed] [Google Scholar]
  • Peltoniemi, M.A., Hagelberg, N.M., Olkkola, K.T., Saari T.I. (2016). Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokin, 55, 1059-1077. [CrossRef] [PubMed] [Google Scholar]
  • Pizon, A.F., Lynch, M.J., Benedict, N.J., Yanta, J.H., Frisch, A., Menke, N.B., Swartzentruber, G.S., King, A.M., Abesamis, M.G., Kane-Gill, S.L. (2018). Adjunct ketamine use in the management of severe ethanol withdrawal. Critical Care Medicine, 46, e 768-771. [Google Scholar]
  • Renteria, R., Baltz, E.T., Gremel C.M. (2018). Chronic alcohol exposure disrupts top-down control over basal ganglia action selection to produce habits. Nat Commun, 9, 211. [CrossRef] [PubMed] [Google Scholar]
  • Rezvani, A. H., Levin, E. D., Cauley, M., Getachew, B., Tizabi, Y. (2017). Ketamine differentially attenuates alcohol intake in male versus female alcohol preferring (P) rats. J Drug Alcohol Res, 6, 236030. [CrossRef] [Google Scholar]
  • Rothberg, R.L., Azhari, N., Haug, N.A. Dakwar, E. (2021). Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: results from a randomized, controlled trial. J Psychopharmacol, 35, 150-158. [CrossRef] [PubMed] [Google Scholar]
  • Ruda-Kucerova, J., Babinska, Z., Luptak, M., Getachew, B., Tizabi, Y. (2018). Both ketamine and NBQX attenuate alcohol drinking in male wistar rats. Neurosci Lett, 666, 175-180. [CrossRef] [PubMed] [Google Scholar]
  • Sabino, V., Narayan, A.R., Zeric, T., Steardo, L., Cottone, P. (2013). mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res, 247, 9-16. [CrossRef] [PubMed] [Google Scholar]
  • Saland, S.K., Kabbaj, M. (2018). Sex differences in the pharmacokinetics of low-dose ketamine in plasma and brain of male and female rats. J Pharmacol Exp Ther, 367, 393-404. [CrossRef] [PubMed] [Google Scholar]
  • Sanders, B., Brula, A.Q. (2021). Intranasal esketamine: From origins to future implications in treatment-resistant depression. J Psychiatr Res, 137, 29-35. [CrossRef] [PubMed] [Google Scholar]
  • Scotton, E., Antqueviezc, B., Vasconcelos, M.F., Dalpiaz, G., Paul Géa, L., Ferraz Goularte, J., Colombo, R., Ribeiro Rosa, A. (2022). Is (R)-Ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. Biochem Pharmacol, 198, 114963. [CrossRef] [PubMed] [Google Scholar]
  • Shah, P., McDowell, M., Ebisu, R., Hanif, T., Toerne, T. (2018). Adjunctive use of ketamine for benzodiazepine-resistant severe alcohol withdrawal: A retrospective evaluation. J Med Toxicol, 14, 229-236. [CrossRef] [PubMed] [Google Scholar]
  • Sheline, Y. I., Price, J. L., Yan, Z., Mintun M. A. (2010). Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci USA, 107, 11020-11025. [CrossRef] [PubMed] [Google Scholar]
  • Shim, I. (2022). Distinct functions of S-Ketamine and R-Ketamine in mediating biobehavioral processes of drug dependency: Comments on Bonaventura et al. Mol Psychiatry. https://doi.org/10.1038/s41380-022-01629-0.20. [PubMed] [Google Scholar]
  • Silvestre, J.S., Pallarés, M., Nadal, R., Ferré, N. (2002) Opposite effects of ethanol and ketamine in the elevated plus-maze test in Wistar rats undergoing a chronic oral voluntary consumption procedure. J Psychopharmacol, 16, 305-312. [CrossRef] [PubMed] [Google Scholar]
  • Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., Palenicek T. (2013). Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett, 34, 287-293. [PubMed] [Google Scholar]
  • Strong, C.E., Kabbaj, M. (2020). Neural mechanisms underlying the rewarding and therapeutic effects of ketamine as a treatment for alcohol use disorder. Front Behav Neurosci, 14, 593860. [CrossRef] [PubMed] [Google Scholar]
  • Strong, C.E., Wright, K.N., Kabbaj, M. (2019). Sex and individual differences in alcohol intake are associated with differences in ketamine self-administration behaviors and nucleus accumbens dendritic spine density. ENeuro 6(6): ENEURO.0221-19.2019. [CrossRef] [PubMed] [Google Scholar]
  • Thomasson, H.R. (1995). Gender differences in alcohol metabolism. Physiological responses to ethanol. Recent Developments in Alcoholism, 12, 163-179. [PubMed] [Google Scholar]
  • Tizabi, Y., Bhatti, B.H., Manaye, K.F, Das, J.R., Akinfiresoye, L. (2012). Antidepressant-like effects of low ketamine dose is associated with increased Hippocampal AMPA/NMDA receptor density ratio in female wistar-kyoto rats. Neuroscience, 213, 72-80. [CrossRef] [PubMed] [Google Scholar]
  • Walsh, Z., Mollaahmetoglu, O.M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., Nutt, D.J., Morgan, C.J.A. (2021). Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open, 8, e19. [Google Scholar]
  • Wei, Y., Chang, L., Hashimoto, K. (2020). A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav, 190, 172870. [CrossRef] [PubMed] [Google Scholar]
  • Williams, N.R., Heifets, B.D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D.M., Rodriguez, C.I., Schatzberg, A.F. (2018). Opioid receptor antagonism attenuates antidepressant effects of ketamine. Am J Psychiatry 175, 1205-1215. [CrossRef] [PubMed] [Google Scholar]
  • Wong, A., Benedict, N.J, Armahizer, M.J., Kane-Gill, S.L. (2015). Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother, 49, 14-19. [CrossRef] [PubMed] [Google Scholar]
  • Worrell, S. D., Gould, T.J. (2021). Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev, 126, 573-589. [CrossRef] [PubMed] [Google Scholar]
  • Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., Yang, W. (2022). Uncovering the underlying mechanisms of ketamine as a novel antidepressant. Front Pharmacol, 12, 740996. [CrossRef] [PubMed] [Google Scholar]
  • Yaden, D.B., Griffiths R.R. (2021). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 4, 568-572. [CrossRef] [PubMed] [Google Scholar]
  • Yao, N., Skiteva, O., Zhang, X., Svenningsson, P., Chergui K. (2018). Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry, 23, 2066-2077. [CrossRef] [PubMed] [Google Scholar]
  • Yoon, G., Petrakis, I.L., Krystal, J.H. (2019) Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry, 76, 337-338. [CrossRef] [PubMed] [Google Scholar]
  • Zanardini, R., Fontana, A., Pagano, R., Mazzaro, E., Bergamasco, F., Romagnosi, G., Gennarelli, M., Bocchio-Chiavetto, L. (2011). Alterations of brain-derived neurotrophic factor serum levels in patients with alcohol dependence. Alcohol Clin Exp Res, 35, 1529-1533. [PubMed] [Google Scholar]
  • Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., Alkondon, M., Yuan, P., Pribut H.J., Singh, N.S., Dossou, K.S., Fang Y., Huang X.P., Mayo, C.L., Wainer, I.W., Albuquerque, E.X., Thompson, S.M., Thomas, C.J., Zarate, C.A. Jr., Gould, T.D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533, 481-486. [CrossRef] [PubMed] [Google Scholar]
  • Zanos, P., Highland, J.N., Stewart, B.W., Georgiou, P., Jenne, C.E., Lovett, J, Morris, P.J., Thomas, C.J., Moaddel, R., Zarate, C.A. Jr., Gould, T.D. (2019). (2R,6R)-Hydroxynorketamine exerts MGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci USA, 116, 6441-6450. [CrossRef] [PubMed] [Google Scholar]
  • Zarate, C.A. Jr., Brutsche, N., Laje, G., Luckenbaugh, D.A., Venkata, S.L., Ramamoorthy, A., Moaddel, R., Wainer, I.W. (2012). Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry, 72, 331-338. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.